With modern treatment, many people living with HIV can expect a near-normal lifespan. A person diagnosed at age 20 who starts treatment early, when their immune system is still strong, can expect to live into their late 70s or early 80s. Without treatment, however, the picture is starkly different: someone who has progressed to AIDS typically survives about three years.
The gap between those two outcomes is almost entirely explained by one factor: whether and when a person starts antiretroviral therapy (ART).
Life Expectancy With Treatment
Treatment has transformed HIV from a death sentence into a manageable chronic condition. A 35-year-old man in the UK who starts treatment while his immune system is still relatively intact and achieves viral suppression can expect to live to about 80, compared to 78 for men in the general population. That’s not a typo. Successfully treated individuals now have what researchers describe as a “normal life expectancy.”
The gains have been dramatic even over the past two decades. In British Columbia, life expectancy at age 20 for men with HIV rose by nearly 24 years between the late 1990s and 2012-2020, climbing from about 44 years old to 68. For women, the increase was about 19 years, reaching a life expectancy of roughly 61 at age 20. That persistent gender gap is still not fully understood, but women with HIV consistently have somewhat lower life expectancy than men in the same treatment cohorts.
European and North American data show similar trends. A 40-year-old woman who started ART after 2015 with a strong immune system had an estimated 42 additional years of life ahead of her, meaning she could expect to live to about 82. For men in the same situation, the estimate was around 39 more years, or roughly age 79.
Why Starting Treatment Early Matters
The single biggest factor in long-term survival is how much damage HIV has already done to the immune system before treatment begins. Doctors measure this by counting CD4 cells, the immune cells HIV targets. A healthy person has roughly 500 to 1,500 of these cells per cubic millimeter of blood. An AIDS diagnosis happens when that count drops below 200.
Starting treatment with a CD4 count above 500 puts life expectancy within reach of the general population. Starting with a count below 200, meaning the immune system is already severely weakened, cuts life expectancy by more than 10 years compared to starting in the 200-350 range. Starting with a count below 100 can mean losing over 20 years of life expectancy compared to the general population.
This is why early testing and early treatment are so critical. A person who learns their status quickly and begins ART before their immune system deteriorates has a fundamentally different prognosis than someone diagnosed late with advanced disease. After five years on treatment, a 35-year-old man who had achieved viral suppression and rebuilt his immune system could expect to live to 80. A man the same age whose immune system remained below 200 cells and who hadn’t achieved viral suppression had a projected lifespan of only 54.
Without Treatment
Left untreated, HIV follows a fairly predictable timeline. Signs of HIV-related illness typically develop within 5 to 10 years, sometimes sooner. The progression from initial HIV infection to an AIDS diagnosis usually takes 10 to 15 years, according to the World Health Organization. Once a person reaches the AIDS stage without treatment, average survival is about three years. If a dangerous opportunistic infection develops, that window can shrink to about one year.
These numbers reflect the natural course of the virus steadily destroying the immune system until the body can no longer fight off infections and cancers that a healthy immune system would easily handle.
What People With HIV Actually Die From
Here’s something that surprises many people: the majority of deaths among treated HIV-positive individuals are not caused by AIDS-related conditions. In high-income countries, 54% to 70% of excess deaths among people on ART come from non-AIDS causes, primarily cardiovascular disease, non-AIDS-related cancers, and liver disease. HIV, even when well controlled, creates chronic low-level inflammation that accelerates aging in the cardiovascular system and other organs.
This means that for someone on effective treatment, the health priorities start to look a lot like those of the general population: managing cholesterol, blood pressure, cancer screening, and lifestyle factors like smoking and exercise. Smoking, in particular, has been shown to reduce life expectancy in people with HIV by more than HIV itself does when the virus is well controlled.
Global Differences in Outcomes
These optimistic survival numbers come mostly from high-income countries where treatment is widely available and healthcare systems can monitor patients regularly. The picture is different in many parts of the world. In sub-Saharan Africa, which carries the heaviest burden of HIV globally, ART access has pushed average life expectancy from 56.5 years in 2010 to 62.3 years in 2024. That’s a remarkable improvement, but still well below what’s achievable with consistent, well-monitored treatment.
The gap comes down to access. Late diagnosis, interrupted drug supplies, limited viral load monitoring, and co-infections like tuberculosis all shorten survival. Where treatment is available, consistent, and started early, outcomes in lower-income countries are improving steadily, but they haven’t yet caught up to the near-normal lifespans seen in well-resourced healthcare systems.
The Bottom Line on Survival
A person diagnosed with HIV today who starts treatment promptly and stays on it can realistically expect to live into their 70s or 80s. A person who has already progressed to AIDS faces a more uncertain path, but even at that stage, starting treatment can dramatically extend life. The key variables are timing of diagnosis, consistent treatment, achieving viral suppression, and managing the same chronic disease risks that affect everyone as they age.